Medicare AdvantageDocumentationMedium impact
[New York] Medication safety alerts: reducing opioid and anticholinergic risk
Anthem BCBS·NY · Internal Medicine, Family Medicine, Geriatrics +3 more·Provider Bulletin
Effective date
Jun 30, 2026
We identified it
Jul 1, 2026
Summary
This is a new Medicare Advantage medication safety policy focusing on reducing harm from high-risk drug combinations: opioid + benzodiazepine overlap (COB) and multiple anticholinergics in older adults (Poly-ACH). The policy emphasizes medication reconciliation, deprescribing, and clinical monitoring at every patient visit. While primarily educational and clinical guidance, it may influence prior authorization decisions and claims review for affected medication combinations.
Action Required
By July 15, 2026: Clinical and billing teams should coordinate to implement medication safety monitoring. Providers must reconcile all medications (Rx + OTC) at every visit and document clinical rationale for patients on concurrent opioids + benzodiazepines (≥30 cumulative days overlap) or multiple anticholinergics (≥2 drugs for ≥30 days in patients ≥65 years). Billing team should flag claims for these high-risk combinations for potential clinical review before submission. Update EMR/EHR alerts to notify providers of these medication combinations at prescribing and refill points. Ensure prior authorization workflows account for naloxone co-prescribing for at-risk patients. Enroll clinical staff in the recommended webinar 'Polypharmacy: Medication Safety in Older Adults' available on Anthem's Health Education & Training portal. Failure to document clinical necessity for high-risk combinations may result in claim denials or Star rating penalties under CMS Part D measures.